There are increasing levels of concern relating to the rapidly evolving novel psychoactive substances/NPS and web markets' scenarios. The paper aims at providing an overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants and hallucinogens. NPS intake is typically associated with the imbalance of a complex range of neurotransmitter pathways/receptors, namely: dopamine; cannabinoid/CB1;
Introduction
Over the last decade, the drug scenario has shown significant levels of changes, with the emergence of a range of novel psychoactive substances (NPS). NPS are typically defined as new narcotic/psychotropic drugs which are not controlled by the United Nations' 1961 Narcotic Drugs/1971 Psychotropic Substances Conventions, but which may pose a public health threat [1] .
However, 'novel' typically refers to molecules that have recently become a reason of current/potential public health concern. At times, although misleading, the terms 'legal highs' or 'research chemicals' have been used as well to describe such substances, with the web playing a major role in shaping this unregulated market. [2] . Overall, there are increasing levels of concern about both the complex pharmacodynamics of these drugs and the appearance of acute/chronic medical and psychopathological manifestations associated with NPS intake. [1] A concurrent use of a range of different NPS, and/or medications, is frequently being reported and this may be a reason of further concern.
The present paper aims at providing an overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants and hallucinogens (for a rapid overview, see Table 1 ).
Methods
We searched Medline/PubMed for studies using the terms "new psychoactive substances", "novel psychoactive substances", "legal highs", "designer drugs", "research chemicals", "smart drugs", "emerging drugs of abuse", "emerging drugs of misuse", "stimulants", "hallucinogenic drugs", "psychedelics", "synthetic cannabimimetics", "synthetic cannabinoids", and "spice".
The search was filtered by "English and human" and limited by publication dates to the last five years. In total, 4159 references were identified; of these, 363 were considered potentially relevant. Some further 35 references were retrieved from specific websites identified by typing the index substance keywords on Google, with selection and analysis of fora posts/threads; and from national/international agencies' reports. After a further thorough screening for eligibility, some 82 papers/documents had finally been considered here as suitable and consistent with the aims of the paper. Methcathinone (ephedrone) selectively generates a release of dopamine (DA) higher than that of serotonin (5-HT). MDPV is a DA selective uptake inhibitor, but selectively blocks the uptake of DA more than 5-HT, and presents with a high abuse potential. [5] MDPV inhibits monoamine uptake at the DA, 5-HT and norepinephrine (NET) transporters, similarly to cocaine. [6, 7] The behavioural effects of mephedrone and MDPV are similar to methamphetamine and cocaine respectively, whilst methylone's are closer to MDMA. [8] MDPV, mephedrone, methcathinone, and naphyrone are potent NET inhibitors. [9] Synthetic cathinones are typically sold as pills, capsules and powders. They are usually snorted/sniffed (insufflated), taken orally by 'bombing' (swallowing the powder wrapped in a cigarette paper), mixed in a drink, or through intravenous injecting.
Synthetic cathinones are often used by consumers for various reasons, including: hallucinogenic experiences, euphoria, mood enhancement, openness, empathy, mental clarity, stimulation, increased energy, and increased libido. [10] Mephedrone possesses a re-dosing risk due to half-life being as short as 1h. [11] By contrast, MDPV is thought to have a half-life of 3-5 h. Several different cathinones are often used together, and this could cause synergistic effects, e.g. as with MDPV and mephedrone. [9] The most common cathinones' adverse reactions are restlessness and anxiety, ranging from mild agitation to severe psychosis. Furthermore, tachycardia, hypertension, abdominal pain, chills, flushing, sweating, hyperthermia, renal failure, rhabdomyolysis, and seizures can also be observed. [1, [12] [13] [14] Paranoid ideation and mood disturbances have been observed in chronic users of both natural and synthetic cathinones. [13] [14] [15] [16] Many synthetic cathinones users report tolerance, dependence and withdrawal symptoms. [17] Injecting use of synthetic cathinones has emerged among specific subpopulations' segments of at least 10 EU countries. [18] In some areas in Europe (e.g. eastern Europe), such injectors account for more than half of all drug injectors, with problem drug users now switching from heroin. The intake of cathinones can occur with high frequency levels, e.g. up to 10-20 times injections per day. MDPV, mephedrone, and 4-MEC are all reported to be injected. A more recent development is the injecting of α-PVP in Ireland. [19] Within the 'Chemsex' (e.g. the use of misusing drugs to increse levels of libido/sexual performances) context, drugs including synthetic cathinones/mephedrone are described as having a significant influence on the risk-taking behaviour of 'men who have sex with men'/MSM population. [20] Some 83 deaths involving synthetic cathinones had been registered by the end of 2014 in England and Wales. [21] Although most fatalities involved mephedrone, increasing numbers of α-PVP and pentedrone deaths are being reported in the EU. Cathinones are typically involved in hangings or other mechanical suicides. [13, 14] 
4,4'-dimethylaminorex (4,4'-DMAR)
4,4'-dimethylaminorex (4,4'-DMAR, "Serotoni"), a derivative of aminorex, is a powerful dopamine/noradrenaline releaser whilst inhibiting the SERT as well. It may be snorted, or ingested, to achieve levels of both elation and increased alertness. The relating anxiety/agitation may last for a number of hours, with the risk of increase in body temperature and cardiorespiratory problems. [22] "Serotoni" has recently been associated with some 35 fatalities in Europe. [ propylphenidate; and isopropylphenidate. 3,4-DCMP is claimed to be more potent than MPH, with a slower onset of action and longer duration. [23] HDMP-28 acts as a triple receptor re-reuptake inhibitor (DA, NE, and 5-HT) in a manner similar to cocaine; it is also claimed to have several times the potency of MPH, but with a shorter duration of action. [23] EPH can also be found as an extra ingredient in psychoactive compounds' mixtures, together with methiopropamine, ephedrine, phenylethylamine, and remaining stimulants. [23, 24] EPH intake can occur orally, intranasally, rectally, or through intramuscular/intravenous injection. Commonly reported dosages are 10-100 mg for oral or intranasal administration, and 5-50 mg for injection.
[25] The mean onset time for the EPH 'high' is around 15 minutes for intranasal, and 25 minutes for oral administration; the mean duration of the effects is 120 minutes for all routes of administration. It has been suggested that, at low doses, EPH encourages increased levels of motor/mental productivity, whilst at higher dosages this may result in a general lack of motor control.
[26] EPH can be found in powder; crystalline; and tablet form.
Common desidered effects reported by users include euphoria, stimulation/increased arousal, improved concentration, sociability, and sexual drive. Conversely, adverse effects reported include muscle tension, palpitations, sweating, appetite loss, anxiety/restlessness, insomnia, paranoia, and auditory/visual hallucinations.
[24] EPH intake has been associated with bizarre/erratic and violent behaviour, suicidality, psychosis, and clinical worsening of paranoid schizophrenia. [23] Tolerance to EPH has been described. Many users report a concurrent intake of a range of substances, and in particular of sedative drugs such as alcohol, benzodiazepines and/or opiates used as 'downers', together with EPH. A 'crash'-like phase after the end of an EPH binge session, with a period of mood lowering and fatigue, has been described. [27] As it might be expected from a short half-life stimulant which boosts DA levels, users report a strong urge/compulsion to re-dose. [23, 27, 28] A significant outbreak of severe soft-tissue infections among drug users who report injecting EPH repeatedly has been recently identified. [23] Twenty-eight fatalities associated with analytically confimed EPH ingestion, mostly in combinationoth other drugs, have been described. Death') are similar to MDMA, although these molecules are already extremely active at lower doses. They may determine a fatal rise in body temperature, euphoria, a sense of full energy, an amplification of sounds/colours and feelings of love/sociability. An increasing number of fatalities have been described following their consumption. [30] Diclofensine is a stimulant that acts as a DA/NE/5-HT reuptake inhibitor. [ Most aminoindanes are available from a range of sources, including the web, as tablets, powder, and capsules/tablets which can be either ingested or snorted.
Amphetamine-type stimulants/novel stimulants
Aminoindanes are used by consumers in search of a range of psychaoctive effects, including: hallucinogenic experiences, euphoria, mood enhancement, openness, empathy, mental clarity, stimulation, increased energy, and increased libido. [41] Aminoindanes are reported to cause eye and skin irritation, as well as gastrointestinal disturbances with nausea, vomiting/diarrhoea, and respiratory tract concerns. Three deaths associated with MDAI use, either alone or in combination, were identified in the UK during 2011-2012, all involving symptoms consistent with serotonin syndrome. [42] Synthetic cocaine analogues Dimethocaine and 4-fluorotropacocaine (pFBT), typically found as white powder, act as DA reuptake inhibitors, resulting in mild stimulant effects.
Similar to cocaine, both substances are being insufflated since following ingestion they would be hydrolysed by the digestive system esterases.
Dimethocaine users report a short-lasting rush, together with levels of increased attention/concentration, talkativeness, and the desire to re-dose.
Adverse/unwanted effects include peripheral vasoconstriction, tachycardia, diaphoresis, muscle twitching, nausea, and vomiting. [41] pFBT is anecdotally reported to cause hypertension, tachycardia, anxiety and temporary psychosis. [41] Further cocaine analogues include RTI-111 (e.g. a potent stimulant acting as an inhibitor of 5-HT, DA and NE reuptake [43] ); RTI-121 and RTI-126. RTI-121 is a potent/long-lasting stimulant acting as a selective DA reuptake inhibitor. [44] RTI-126, [45] on the other hand, may present with a potency which is 5-fold higher than that of cocaine. When snorted, these compounds are associated with alertness, euphoria, talkativeness, insomnia, prolonged residual tension/anxiety, and crash-like symptoms. [1] Hallucinogens: synthetic cannabimimetics; psychedelic phenetylamines; and 'Spice' preparations are composed by both a dried plant base, to mimic the 'grass effect' of female cannabis dried inflorescences, and a mixture of SC which are sprayed on it. SC dispersed in the grass preparation look like hashish, with capsules and e-liquid formulations being available as well. SC have also been found in tablets and sprayed on herbal cannabis. SC can be found on the web, from 'head-shops', gas stations, and from an ever expanding range of other outlets. [52] Their intake can occur through inhalation from a joint/bhong/pipe or using a vaporizer. Other ways of intake include: insufflation, oral ingestion, rectal administration and injection. [1] Misusers are often young males, choosing Spice instead of cannabis for its low cost; favourable legal status; [41] easy availability; mis-perception that SC are natural, and not synthetic, molecules; and undetectability in routine urine screening tests. [53, 54] The nondetectability of SC make also Spice very attractive for sub-populations undergoing regular drug tests. [10] Spice products are almost always laced with multiple SC in a single preparation. [1] Hence, there is a potential for drug-drug interactions between multiple SC in a single product, and this may contribute to the abuse-related and synergistic effects of these compounds. Some SC metabolites, furthermore, retain levels of both affinity and activity for CB-1 receptors, hence contributing to the toxicity of the products. [55] The recent trend of SC fluorination may increase the compounds' lipophilicity, hence promoting the absorption through biological membranes/blood brain barrier, possibly enhancing the SC overall toxicity. [55] The total lack of product quality control may lead to significant differences in concentration ('hot-spots') of SC present in herbal incenses or eliquids. [46, 55] In comparison with cannabis, use of SC may be characterized by quicker 'kick off' effects; significantly shorter duration of action; larger levels of hangover effects; and more intense visual hallucinations, paranoid feelings, and behavioural dyscontrol. [46, 56] The acute SC intoxication is characterized by a short-lived clinical picture with reported signs/symptoms of elevated heart rate/blood pressure levels; visual/auditory hallucinations; mydriasis; agitation/anxiety; hyperglycaemia; dyspnoea/tachypnoea; and nausea/vomiting. [1] Other psychiatric and neurological effects include: suicidal ideation/selfinjurious behaviour; aggressive behaviour; panic attacks; cognitive impairment; thought disorganisation; psychosis; agitated/excited delirium; nystagmus; seizures; hyperemesis; encephalopathy; acute kidney injury; rhabdomyolysis; hyperthermia; serotonin syndrome; toxic hepatitis/liver failure; coma; severe dysrhythmias/cardiotoxic effects; and stroke. [1, 56] Long-term SC misuse may also be associated with tolerance, dependence, and a severe prolonged withdrawal syndrome, characterized by drug craving, tachycardia, tremor, profuse sweating and diarrhoea, nightmares/insomnia, headache, anxiety/irritability, mood swings, feelings of emptiness/depressive symptoms, and somatic complaints. Psilocin hallucinogenic effects occur within the first 2 hours after oral intake and last up to 4-8 hours. [74] Psilocin is a partial 5-HT 2A agonist, with little dopaminergic or noradrenergic activity. [75, 76] Bufotenin (aka '5-OH-DMT') is found in the skin of various species of the toad Bufo genus; in mushrooms such as Amanita; and in plants such as Anadenanthera and Piptoderma peregrina. [77] It acts on 5-HT 2A receptors. [78] Alongside these naturally occurring tryptamines, a rapidly increasing number with erratic IM absorption. [81] Benzodiazepines, however, need frequent re-dosing/high dosages to achieve adequate sedative effect, and this may be a problem if clients have co-ingested alcohol.
Where patients cannot be controlled with benzodiazepines alone, propofol and/or antipsychotics (especially when paranoia and psychosis are being identified) may be considered, although this may further contribute to the acute toxicity effects of the abused substances. Both haloperidol and droperidol (5-10 mg IM or IV) have been suggested as reasonable options. [81] Aripiprazole, quetiapine, risperidone, and olanzapine can also be used, although the levels of evidence regarding their use for the undifferentiated agitation patient is limited. [81] Treatment of hyperthermia needs to be aggressively planned, and this typically involves cooling measures and, once an IV line is available, focus should be on control of rhabdomyolysis with intravenous fluid administration. [1; 81] The serotonin syndrome is managed using benzodiazepines and cyproheptadine. [1] Inpatient admission, possibly to intensive care units, may at times be needed.
Five-year view
Indeed, future studies will provide better levels of NPS clinical and basic pharmacology-related knowledge, so that better tailored management/treatment guidelines can be made available.
Health professionals' education involving knowledge on NPS health harms, potential interventions, and referral pathways is lacking. Future NPS-related tutoring activities will allow clinicians to promote health prevention and education activities, which in turn would reduce the negative social impact of NPS misuse; unnecessary hospital admissions; and avoidable fatalities. [82] Future approaches will consider as well the role of web-based preventative strategies in targeting youngsters/vulnerable individuals at risk of approaching the NPS market.
Although current general population surveys suggest relatively low levels of NPS use, at least if compared with well-known scheduled substances such as THC, cocaine and heroin, this may change. The online market of novel psychoactive substances is unfortunately developing far more rapidly than academic research. Hence, it is more than likely that over the next 5 years or so the number of NPS will continue to rise. Similarly to Poland and Ireland, however, a brand new legislation focussing on NPS is expected to come into effect in the UK in April 2016. As a result of this, it is speculated that most of the so called 'legal highs'/'research chemicals', now considered as technically 'legal', will be outlawed. Since at present a sizeable proportion of the NPS are made available to customers through the most popular 'open web' search engines, one could hypothesize that over the next few years the NPS market will gradually expand and/or move to the 'deep web', and especially to its most hidden portion, e.g. the 'DarkNet'. [2] It is hence here speculated that most transactions of NPS will occur in the future with the help of both 'ad hoc', deep-web tailored, browsers and a range of 'crypto currencies', some of which are already available for use. Current research activities, coordinated from our group, are already focussing on these possible future scenarios.
Key issues

•
Over the last decade, the drug scenario has shown significant levels of changes, with the emergence of a range of novel psychoactive substances (NPS). The web may play a major role in shaping this unregulated market
• An overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants (e.g. synthetic cathinones; 4-4-DMAR; methylphenidate-like NPS; amphetamine-type stimulants;
aminoindanes; and cocaine analogues); and hallucinogens (synthetic cannabimimetics; psychedelic phenethylamines and tryptamines) is here provided (see Table 1 ).
• NPS intake is typically associated with the imbalance of a range of neurotransmitter pathways/receptors, which in turn may be followed by the occurrence of a range of psychopathological disturbances, due to: a) increased central dopamine levels, associated with the intake of most of these substances, including novel psychedelic phenethylamines, stimulants, synthetic cathinones and 4,4'-DMAR; b) cannabinoid CB1 receptor activation, achieved with synthetic cannabimimetics; and c) intense 5-HT2A receptor activation, reported with both NBOMe compounds and latest tryptamine derivatives.
• NPS intake usually fails to be identified with standard drug screening tests. Advanced tests can be performed, but they are not generally available in the acute setting and are used mainly for forensic investigations.
• The initial management of these patients should focus on decreasing levels of both self-/outward-directed aggression and agitation. Due to the complex, and at times unknown, pharmacology of the NPS/other psychoactives ingested by the client, benzodiazepines may be considered as agents of choice
• It is more than likely that over the next 5 years or so the number of NPS will continue to rise. A brand new legislation focussing on NPS is expected to come into effect in in the UK April 2016. It is speculated that over the next few years the NPS market will gradually expand and/or move to the 'deep web', and especially to its most hidden portion, e.g. the 'DarkNet'.
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